ReNeuron has announced a proposed 100 for 1 share consolidation. The Board believes the consolidation will increase ReNeuron’s marketability in both the UK and abroad. The General Meeting to approve the consolidation is on the 23rd January. ReNeuron continues to progress its stem cell therapy candidates. A Phase IIb (PISCES III) trial evaluating CTX stem cell therapy for stroke in on track to commence in H1 2018 with data in late 2019. Initial Phase II data from the ongoing Phase I/II trial eval ....
05 Jan 2018
Proposed share consolidation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Proposed share consolidation
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
05 Jan 2018 -
Author:
Sheena Berry -
Pages:
3
ReNeuron has announced a proposed 100 for 1 share consolidation. The Board believes the consolidation will increase ReNeuron’s marketability in both the UK and abroad. The General Meeting to approve the consolidation is on the 23rd January. ReNeuron continues to progress its stem cell therapy candidates. A Phase IIb (PISCES III) trial evaluating CTX stem cell therapy for stroke in on track to commence in H1 2018 with data in late 2019. Initial Phase II data from the ongoing Phase I/II trial eval ....